Hemispherx's fatigue drug to be reviewed again by FDA, WSJ reports

theflyonthewall.com

A potential treatment for chronic fatigue syndrome will be reviewed again this week when an FDA panel looks at Hemispherx Biopharma's (HEB) experimental drug Ampligen, reports the Wall Street Journal. The drug has been in development for chronic fatigue syndrome for about two decades, but in 2009 the FDA refused to approve it, saying clinical studies submitted for approval of the product didn't provide "credible evidence" of the drug's effectiveness.

Rates

View Comments (2)